ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2806

A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study

John A. Reynolds1,2, Mumtaz Khan3, Tracy A. Briggs4, Gillian Rice5, Yanick Crow5, Ben Parker6 and Ian N. Bruce1,7, 1NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 2Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 3Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 4Institute of Human Development, University of Manchester, Manchester, United Kingdom, 5Manchester Academic Health Science Centre, Institute of Human Development, University of Manchester, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 7Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Connective tissue diseases, Interferons and systemic lupus erythematosus (SLE), Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Type I interferon has been implicated in the pathogenesis of systemic lupus erythematosus (SLE), but much less is known about its role in other connective tissue diseases (CTDs).  We aimed to determine the prevalence of a type I interferon signature across CTDs, and identify factors associated with elevated interferon activity.

Methods: Subjects were recruited from Central Manchester University Hospitals, UK between May 2014 and March 2016.  Patients were categorised by their physician diagnosis into SLE, undifferentiated CTD (UCTD), mixed CTD (MCTD), Sjogren’s syndrome (SS) and systemic sclerosis (SSc). RT-qPCR was performed on cDNA derived from whole blood and the median fold change of six interferon-simulated genes (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1) was compared with the median of healthy controls, to create an interferon sensitive gene (ISG) score for each patient.  Scores higher than the mean of the controls plus two sd (>2.466) were designated as positive.

Results: We recruited 92 subjects with a median (IQR) age of 48.3 (33.5, 57.4) years.  86 (93.5%) were female, 70/92 (76%) were Caucasian and the median disease duration was 7.21 (3.06, 13.78) years.  The most commonly present autoantibodies were anti-U1RNP (25/92 [27.2%]), anti-Ro/SSA (24/92 [26.1%]) and anti-dsDNA (22/92 [23.9%]).  In total, 58/92 (63%) subjects had at least 1 positive autoantibody (Ro, La, Smith, RNP, chromatin, Scl-70, dsDNA or anti-CCP). Across all subjects, 31/92 (33.7%) had a positive ISG score.  ISG scores were significantly higher in patients with SLE or MCTD, compared to UCTD (p=0.003 across all groups) (figure).  All 3 SSc patients had a negative ISG score. In univariate logistic regression models, a positive ISG was significantly associated with the presence of anti-Smith, Ro, RNP and chromatin antibodies.  Rheumatoid factor (but not anti-CCP) was also associated with a positive ISG score.  These antibodies all remained significant after adjustment for age, gender, ethnicity (Caucasian or non-Caucasian) and clinical diagnosis (table).  A significant association was observed between the number of autoantibodies (range 0-5) and a positive ISG score (OR 2.6 [1.73, 3.81], p<0.001).  In a multivariable logistic regression model this observation remained significant after adjustment for age, gender, ethnicity and diagnosis (OR 2.2 [1.44, 3.50], p<0.001).

Conclusion: Expression of a type I interferon signature differs across CTD subtypes and is not observed in UCTD and SSc.  The strongest factor associated with a positive ISG score was the type and number of autoantibodies, especially those binding to RNA antigens.

Unadjusted model

Adjusted model*

* for age, gender, ethnicity and diagnosis

OR 95% CI OR 95% CI
Anti-dsDNA 2.50 (0.934, 6.684) 1.55 (0.521, 4.623)
Anti-Smith 12.2 (3.111, 47.914) 14.5 (2.475, 85.491)
Anti-RNP 8.04 (2.883, 22.447) 5.19 (1.517, 17.749)
Anti-Ro 9.37 (3.250, 26.995) 13.0 (3.400, 49.542)
Anti-La 2.30 (0.771, 6.890) 2.48 (0.589, 10.421)
Anti-chromatin 7.55 (2.512, 22.683) 5.69  (1.512, 21.406)
Rheumatoid factor 5.33 (1.631, 17.442) 11.5 (2.100, 63.175)
Anti-scl70 1.55 (0.320, 7.293) 2.32 (0.373, 14.512)
Anti-CCP 1.33 (0.211, 8.428) 1.27 (0.114, 14.091)

Disclosure: J. A. Reynolds, None; M. Khan, None; T. A. Briggs, None; G. Rice, None; Y. Crow, None; B. Parker, None; I. N. Bruce, None.

To cite this abstract in AMA style:

Reynolds JA, Khan M, Briggs TA, Rice G, Crow Y, Parker B, Bruce IN. A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-type-i-interferon-signature-is-associated-with-autoantibody-profiles-in-connective-tissue-diseases-results-from-the-lupus-extended-autoimmune-phenotype-leap-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-type-i-interferon-signature-is-associated-with-autoantibody-profiles-in-connective-tissue-diseases-results-from-the-lupus-extended-autoimmune-phenotype-leap-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology